HOME > TOP STORIES

TOP STORIES

ACADEMIA Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi

January 22, 2024
BUSINESS LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO

January 19, 2024
REGULATORY Market Expansion Re-Pricing to Hit 23 Meds in April, Opdivo Faces Yet Another Cut in Spillover

January 18, 2024
BUSINESS Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan

January 18, 2024
BUSINESS Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing

January 18, 2024
BUSINESS Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November

January 17, 2024
REGULATORY MHLW Issues Notification to Clarify Orphan Designation Criteria

January 17, 2024
COMMENTARY Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers

January 17, 2024
REGULATORY FY2024 Reform Will Bolster Rewards for Innovation to Eradicate Drug Lag/Loss: LDP Policy Bigwig

January 16, 2024
REGULATORY New LLP Coverage Rule Aimed to Transform Industry Rather Than Eke Out Savings: LDP Social Security Chief

January 15, 2024
BUSINESS GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine

January 15, 2024
BUSINESS Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President

January 12, 2024
REGULATORY MHLW Study Underway on Lab Monkey Shortage, Research Team Frets Dependence on Specific Sources

January 11, 2024
BUSINESS New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform

January 10, 2024
REGULATORY Handling of Big-Seller Candidates Is Top Priority as Japan Seeks Good Budget Balance: Minister

January 10, 2024
ORGANIZATION FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025

January 9, 2024
BUSINESS Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake

January 9, 2024
BUSINESS Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?

January 5, 2024
BUSINESS After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula

January 5, 2024
REGULATORY FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director

December 28, 2023

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…